Marina Biotech, Inc.

Sirna Therapeutics, Inc.

Kathy L Fosnaugh

Michael E Houston, Jr

Shaguna Seth

Steven C Quay

Mary Gallagher Prieve

Pierrot Harvie

Roger C Adami

Renata Fam

Leonid Beigelman

James A McSwiggen

Chandra Vargeese

Nassim Usman

Weimin Wang

James D Thompson

James Mcswiggen

Shawn Patrick Zinnen

Peter Haeberli

Tongqian Chen

Pamela Pavco

David Morrissey

Bharat Chowrira

Narendra Vaish

Dennis G Macejak

Narendra K Vaish

Michael V Templin

Sharon F Jamison

Dennis Macejak

Victor Mokler

Sharon Jamison

Michael Houston

Shawn Zinnen

This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).

Therapeutics with conformationally restricted monomers

This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Tyrosine-based lipids for delivery of therapeutics

This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Arginine-based lipids for delivery of therapeutics

Amino acid lipids and uses thereof

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Growing community of inventors

Bellevue, WA, United States of America

Kathy L Fosnaugh